Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopurine Anhydrous SCHEMBL8843 | 0.98 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL5144252 | 0.96 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL7199288 | 0.82 | — | — | |
| Mercaptopurine Anhydrous SCHEMBL12476114 | 0.81 | ALDH1A1 (0.62) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL2895675 | 0.76 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL2772644 | 0.76 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL18317326 | 0.75 | LMNA (0.51) | LMNAALDH1A1HBBSMN1; SMN2 | |
| Adenine SCHEMBL2428538 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL2428541 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL8110 | 0.73 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115705-A1 | Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-11 | — | — | US | claimed |
| CN-117295505-A | Modulation of the milk philin subfamily 3 member A1 (BTN 3A1, CD 277) | 加利福尼亚大学董事会 | 2023-12-26 | — | — | CN | claimed |
| EP-4288074-A1 | REGULATION OF BUTVROPHILIN SUBFAMILY 3 MEMBER A1 (BTN3A1, CD277) | The Regents of The University of California Santa Cruz (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2022170344-A1 | REGULATION OF BUTVROPHILIN SUBFAMILY 3 MEMBER A1 (BTN3A1, CD277) | MARSON ALEXANDER (US) | 2022-08-11 | — | — | WO | claimed |
| US-20140294972-A1 | Oral Suspension | NOVA BIO-PHARMA TECHNOLOGIES LIMITED (GB) | 2014-10-02 | — | — | US | claimed |
| US-8765712-B2 | Agent for preventing and treating pityriasis versicolor | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) | 2014-07-01 | — | — | US | claimed |
| WO-2013034931-A1 | ORAL SUSPENSION | NOVA BIO-PHARMA TECHNOLOGIES LIMITED (GB) | 2013-03-14 | — | — | WO | claimed |
| US-20120129800-A1 | Agent For Preventing And Treating Pityriasis Versicolor | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2012-05-24 | — | — | US | claimed |
| EP-2175860-A2 | NR4A AGONISTS (6-MERCAPTOPURINE) FOR INHIBITION OF NON-OCULAR SCARRING | Renovo Limited (GB) | 2010-04-21 | — | — | EP | claimed |
| WO-2009016379-A2 | NR4A AGONISTS ( 6-MERCAPTOPURINE) FOR INHIBITION OF NON-OCULAR SCARRING | RENOVO LIMITED (GB) | 2009-02-05 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5854231-A | Pharmaceutical composition for inhibiting the growth of cancers | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-29 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5043237-A | Inhibitor-containing photohardenable electrostatic master compositions having improved resolution | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-27 | — | — | US | claimed |
| EP-0436948-A2 | Inhibitor-containing photohardenable compositions having improved resolution | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-17 | — | — | EP | claimed |
| CN-120004760-A | Ultrasonic activated azido precursor, prodrug and application | 中国科学院长春应用化学研究所 | 2025-05-16 | — | — | CN | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240377736-A1 | PHOTOSENSITIVE COMPOSITION | ARKEMA FRANCE (FR) | 2024-11-14 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-3604310-B1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-09-11 | — | — | EP | disclosed |
| EP-4401983-A1 | PHOTOSENSITIVE COMPOSITION | ARKEMA FRANCE (FR) | 2024-07-24 | — | — | EP | disclosed |
| US-11986479-B2 | Combination drug products for treating patients suffering from one or more medical conditions caused by coronavirus infection, including by SARS-CoV-2, its alpha, beta, delta, or omicron variants and sub variants | PharSoln, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-118019645-A | Photosensitive composition | 阿科玛法国公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11959065-B2 | Bacillus megaterium bioactive compositions and metabolites | PRO FARM GROUP, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240115705-A1 | Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-11 | — | — | US | disclosed |
| US-20240024329-A1 | COMBINATION DRUG PRODUCTS FOR TREATING PATIENTS SUFFERING FROM ONE OR MORE MEDICAL CONDITIONS CAUSED BY CORONAVIRUS INFECTION, INCLUDING BY SARS-CoV-2, ITS ALPHA, BETA, DELTA, OR OMICRON VARIANTS AND SUB VARIANTS | PharSoln, Inc. (US) | 2024-01-25 | — | — | US | disclosed |
| CN-117295505-A | Modulation of the milk philin subfamily 3 member A1 (BTN 3A1, CD 277) | 加利福尼亚大学董事会 | 2023-12-26 | — | — | CN | disclosed |
| EP-4288074-A1 | REGULATION OF BUTVROPHILIN SUBFAMILY 3 MEMBER A1 (BTN3A1, CD277) | The Regents of The University of California Santa Cruz (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023041579-A1 | PHOTOSENSITIVE COMPOSITION | ARKEMA FRANCE (FR) | 2023-03-23 | — | — | WO | disclosed |
| EP-4151410-A1 | PHOTOSENSITIVE COMPOSITION | ARKEMA FRANCE (FR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220315885-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | MARRONE BIO INNOVATIONS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-11446304-B2 | CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2022-09-20 | — | — | US | disclosed |
| WO-2022170344-A1 | REGULATION OF BUTVROPHILIN SUBFAMILY 3 MEMBER A1 (BTN3A1, CD277) | MARSON ALEXANDER (US) | 2022-08-11 | — | — | WO | disclosed |
| US-11384332-B2 | Bacillus megaterium bioactive compositions and metabolites | MARRONE BIO INNOVATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11219895-B2 | Blood analysis cartridge | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-11 | — | — | US | disclosed |
| US-20210346388-A1 | CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2021-11-11 | — | — | US | disclosed |
| US-20210308674-A1 | BLOOD ANALYSIS CARTRIDGE | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-07 | — | — | US | disclosed |
| EP-3854401-A1 | CDC7-INHIBITING PURINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-07-28 | — | — | EP | disclosed |
| EP-3155395-B1 | METHODS AND COMPOSITIONS FOR STABILIZATION OF NUCLEIC ACIDS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES | BIOMATRICA INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210060016-A1 | ANTICANCER AGENT | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20210001333-A1 | MICROFLUIDIC DEVICE FOR MEASURING THE ENZYMATIC ACTIVITY OF THIOPURIN S-METHYLTRANSFERASE | KING ABDULAZIZ UNIVERSITY (SA) | 2021-01-07 | — | — | US | disclosed |
| EP-3733206-A1 | ANTICANCER AGENT | Japanese Foundation For Cancer Research (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200267991-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | MARRONE BIO INNOVATIONS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10645936-B2 | Bacillus megaterium bioactive compositions and metabolites | MARRONE BIO INNOVATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10602743-B2 | Method of inducing drought/salt tolerance using Bacillus megaterium | MARRONE BIO INNOVATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200093828-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2020-03-26 | — | — | US | disclosed |
| WO-2020058558-A1 | CDC7-INHIBITING PURINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2020-03-26 | — | — | WO | disclosed |
| US-20200061062-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3604310-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-02-05 | — | — | EP | disclosed |
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180360832-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2018-12-20 | — | — | US | disclosed |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180042241-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | PRO FARM GROUP, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9801386-B2 | Bacillus megaterium bioactive compositions and metabolites | MARRONE BIO INNOVATIONS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170198335-A1 | Stabilization of Non-Denatured Polypeptides, Nucleic Acids, and Exosomes in a Blood Sample at Ambient Temperatures | BIOMATRICA, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-9487772-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| EP-3083617-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2016-10-26 | — | — | EP | disclosed |
| WO-2014028520-A9 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | MARRONE BIO INNOVATIONS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| CN-105829308-A | Isochromene derivatives as phosphoinositide 3-kinase inhibitors | 奇斯药制品公司 | 2016-08-03 | — | — | CN | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3029041-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS Corporation (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| EP-2223922-B1 | Inhibitors of human phosphatidyl-inositol 3-kinase delta | ICOS CORP (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150305346-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | MARRONE BIO INNOVATIONS, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9084428-B2 | Bacillus megaterium bioactive compositions and metabolites | MARRONE BIO INNOVATIONS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2015091685-A1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-25 | — | — | WO | disclosed |
| EP-2885399-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | Marrone Bio Innovations, Inc. (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| US-20150118311-A1 | Highly Penetrative Nanocarriers for Treatment of CNS Disease | Yale Universit (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140294972-A1 | Oral Suspension | NOVA BIO-PHARMA TECHNOLOGIES LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-8765712-B2 | Agent for preventing and treating pityriasis versicolor | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140051571-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | PRO FARM GROUP, INC. | 2014-02-20 | — | — | US | disclosed |
| WO-2014028520-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | MARRONE BIO INNOVATIONS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-8653077-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-02-18 | — | — | US | disclosed |
| US-8637533-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-8623881-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-01-07 | — | — | US | disclosed |
| US-8586739-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1834977-B1 | OPTICAL REFRACTIVE INDEX-MODIFYING POLYMER COMPOSITION, HOLOGRAPHIC RECORDING MATERIAL AND METHOD OF CONTROLLING REFRACTIVE INDEX | NITTO DENKO CORP (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8492389-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| WO-2013034931-A1 | ORAL SUSPENSION | NOVA BIO-PHARMA TECHNOLOGIES LIMITED (GB) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012146667-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| EP-2518071-A1 | Imidazopyridine derivatives as PI3K inhibitors | Almirall, S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2491923-A2 | Combinations of therapeutic agents for treating cancer | Novartis AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-07-05 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120129800-A1 | Agent For Preventing And Treating Pityriasis Versicolor | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1669378-B1 | LIGHT REFRACTIVE INDEX MODULATION POLYMER COMPOSITION AND METHOD OF CONTROLLING REFRACTIVE INDEX | NITTO DENKO CORP (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2359818-A1 | Combination of LBH589 with HSP 90 inhibitors for treating cancer | Novartis AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| EP-1278748-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2011-01-27 | — | — | US | disclosed |
| EP-2223922-A2 | Inhibitors of human phosphatidyl-inositol 3-kinase delta | ICOS Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| EP-2220089-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2010-08-25 | — | — | EP | disclosed |
| US-7781124-B2 | Hologram recording material | NITTO DENKO CORPORATION (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20100204248-A1 | MEDICAMENTS AND METHODS FOR INHIBITION OF NON-OCULAR SCARRING | RENOVO LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-7759361-B2 | treating a cancer, autoimmune diseases and cardiovscular disorders comprising administering drugs such as Isobutyric acid 2-isobutyryloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-ylmethyl ester; antiproliferative agents | APREA AB (SE) | 2010-07-20 | — | — | US | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7727679-B2 | Optical refractive index-modifying polymer composition, hologram recording material and method of controlling refractive index | NITTO DENKO CORPORATION (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-2175860-A2 | NR4A AGONISTS (6-MERCAPTOPURINE) FOR INHIBITION OF NON-OCULAR SCARRING | Renovo Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| CN-101626758-A | Combination of LBH589 and other therapeutic agents for the treatment of cancer | NOVARTIS AG | 2010-01-13 | — | — | CN | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1450822-B1 | Polyalkylene oxide conjugates of thiol-containing drugs | ENZON INC (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2097422-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | Eli Lilly & Co. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7566745-B2 | Photochemically refractive-index-changing polymer, photochemically refractive-index-changing polymer composition, and method of refractive index regulation | NITTO DENKO CORPORATION (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009064802-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ELI LILLY & CO. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009016379-A2 | NR4A AGONISTS ( 6-MERCAPTOPURINE) FOR INHIBITION OF NON-OCULAR SCARRING | RENOVO LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| CN-101356189-A | Hepatocyte growth factor intron fusion proteins | RECEPTOR BIOLOGIX INC (US) | 2009-01-28 | — | — | CN | disclosed |
| US-20080305404-A1 | Which can vary refractive index upon irradiation with visible light laser and exhibits an excellent transparency after the modulation without requiring any conventional complicated procedure; syndiotactic acrylic ester polymer with side chain vinyl group, and specific photopolymerization initiator | NITTO DENKO CORPORATION (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1954714-A2 | HEPATOCYTE GROWTH FACTOR INTRON FUSION PROTEINS | Receptor Biologix, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1939203-A2 | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform | ICOS Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1492803-B1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | GRUENENTHAL GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008064018-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ELI LILLY & CO. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080103110-A1 | Compounds | DRUG DISCOVERY LABORATORY AS (NO) | 2008-05-01 | — | — | US | disclosed |
| US-7358235-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1873593-A1 | HOLOGRAM RECORDING MATERIAL | NITTO DENKO CORPORATION (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-20070259889-A1 | Protein Binding Compounds | DRUG DISCOVERY LABORATORY AS (NO) | 2007-11-08 | — | — | US | disclosed |
| EP-1834977-A1 | OPTICAL REFRACTIVE INDEX-MODIFYING POLYMER COMPOSITION, HOLOGRAM RECORDING MATERIAL AND METHOD OF CONTROLLING REFRACTIVE INDEX | NITTO DENKO CORPORATION (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-20070161081-A1 | Hepatocyte growth factor intron fusion proteins | RECEPTOR BIOLOGIX, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1804838-A2 | DRUG CONJUGATES OF LONG CHAIN FATTY ACID OR ESTER MOIETIES AS PROTEIN BINDING PRODRUGS | Drug Discovery Laboratory AS (NO) | 2007-07-11 | — | — | EP | disclosed |
| US-20070142370-A1 | Azabicyclooctan-3-one derivatives and use thereof | APREA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070128523-A1 | Optical refractive index-modifying polymer composition, hologram recording material and method of controlling refractive index | NITTO DENKO CORPORATION (JP) | 2007-06-07 | — | — | US | disclosed |
| WO-2007058776-A2 | HEPATOCYTE GROWTH FACTOR INTRON FUSION PROTEINS | RECEPTOR BIOLOGIX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070099871-A1 | Bioreductively-activated prodrugs | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| US-20070066705-A1 | Photochemically refractive-index-changing polymer, photochemically refractive-index-changing polymer composition, and method of refractive index regulation | NITTO DENKO CORPORATION (JP) | 2007-03-22 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-1727817-A1 | AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF | APREA AB (SE) | 2006-12-06 | — | — | EP | disclosed |
| EP-1669378-A1 | LIGHT REFRACTIVE INDEX MODULATION POLYMER, LIGHT REFRACTIVE INDEX MODULATION POLYMER COMPOSITION AND METHOD OF CONTROLLING REFRACTIVE INDEX | NITTO DENKO CORPORATION (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1663181-A2 | PROTEIN BINDING COMPOUNDS | Drug Discovery Laboratory AS (NO) | 2006-06-07 | — | — | EP | disclosed |
| US-7033583-B2 | Polymeric thiol-linked prodrugs | ENZON PHARMACEUTICALS, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1450822-A4 | POLYMERIC THIOL-LINKED PRODRUGS | ENZON INC (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2006030217-A2 | DRUG CONJUGATES OF LONG CHAIN FATTY ACID OR ESTER MOIETIES AS PROTEIN BINDING PRODRUGS | DRUG DISCOVERY LABORATORY AS (NO) | 2006-03-23 | — | — | WO | disclosed |
| EP-1613612-A2 | BIOREDUCTIVELY-ACTIVATED PRODRUGS | Angiogene Pharmaceuticals Limited (GB) | 2006-01-11 | — | — | EP | disclosed |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005090341-A1 | AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF | APREA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
| US-6949535-B2 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050096293-A1 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | disclosed |
| WO-2005025552-A2 | PROTEIN BINDING COMPOUNDS | DRUG DISCOVERY LABORATORY AS (NO) | 2005-03-24 | — | — | WO | disclosed |
| US-6846525-B2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1492803-A1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-20040202825-A1 | RECORDING SHEETS CONTAINING PURINE, PYRIMIDINE, BENZIMIDAZOLE, IMIDAZOLIDINE, URAZOLE, PYRAZOLE, TRIAZOLE, BENZOTRIAZOLE, TETRAZOLE, AND PYRAZINE COMPOUNDS | XEROX CORPORATION | 2004-10-14 | — | — | US | disclosed |
| WO-2004085421-A2 | BIOREDUCTIVELY-ACTIVATED PRODRUGS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
| US-6800620-B2 | CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS | ICOS | 2004-10-05 | — | — | US | disclosed |
| EP-1450822-A2 | POLYMERIC THIOL-LINKED PRODRUGS | ENZON, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1438052-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL−INOSITOL 3−KINASE DELTA | ICOS CORPORATION (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6667300-B2 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003084975-A1 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2003-10-16 | — | — | WO | disclosed |
| EP-1352910-A1 | New analogs of nitrobenzylthioinosine | Grünenthal GmbH (DE) | 2003-10-15 | — | — | EP | disclosed |
| US-20030147844-A1 | Polymeric thiol-linked prodrugs | BELROSE PHARMA INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003039479-A2 | POLYMERIC THIOL-LINKED PRODRUGS | ENZON, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003035075-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1278748-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | disclosed |
| WO-2001081346-A2 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5659348-A | APPLYING TO A SUBSTRATE | XEROX CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0397529-B1 | Photohardenable electrostatic element with improved environmental latitude | DU PONT (US) | 1994-11-23 | — | — | EP | disclosed |
| EP-0343666-B1 | Correct-reading images from photopolymer electrographic master | DU PONT (US) | 1994-08-03 | — | — | EP | disclosed |
| EP-0352774-B1 | Photopolymerisation sensitizer active at longer wavelength | DU PONT (US) | 1994-06-22 | — | — | EP | disclosed |
| US-5288528-A | Decomposing, repolymerizing additoin polymers; chain transfer agent or initiator present; molecular weight control | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0331511-B1 | 6-SUBSTITUTED PURINYL PIPERAZINE DERIVATIVES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5164390-A | Cardiac disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| US-5145760-A | POSITIVE-WORKING PHOTOSENSITIVE ELECTROSTATIC MASTER WITH IMPROVED INVIRONMENTAL LATITUDE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-08 | — | — | US | disclosed |
| EP-0186454-B1 | 6-PURINYL N-(2-CHLOROETHYL) CARBAMATE AND THIOCARBAMATE, A PROCESS FOR THEIR PREPARATION AND USE THEREOF | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1992-04-08 | — | — | EP | disclosed |
| US-5096790-A | Cyclopentanone, 2,5-bis-(benzo(i,j)quinolizine)methylene, photoresist | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-17 | — | — | US | disclosed |
| US-5066652-A | ANTIULCER AGENTS | CHIESI FARMACEUTICI S.P.A. (IT) | 1991-11-19 | — | — | US | disclosed |
| US-5064740-A | Binder blend, masters/duplication/; good electrostatic and electroconductive properties | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0454385-A1 | Process for preparing optically active isomers of 6-substituted purinyl piperazine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-10-30 | — | — | EP | disclosed |
| US-5043237-A | Inhibitor-containing photohardenable electrostatic master compositions having improved resolution | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| WO-1991011031-A1 | PROCESSES FOR MAKING THIN FILMS AND CIRCUIT ELEMENTS OF HIGH TEMPERATURE SUPERCONDUCTORS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-25 | — | — | WO | disclosed |
| EP-0436948-A2 | Inhibitor-containing photohardenable compositions having improved resolution | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-17 | — | — | EP | disclosed |
| US-5028503-A | Photohardenable electrostatic element with improved backtransfer characteristics | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-02 | — | — | US | disclosed |
| US-5021574-A | Cardiotonic agents, antiarrhythmia agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| US-5006434-A | Blend of binders with different glass transition temperatures, heat and moisture resistance | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0418855-A1 | Photohardenable electrostatic element with improved backtransfer characteristics | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-27 | — | — | EP | disclosed |
| US-4987230-A | DERIVED FROM CYCLIC KETONES AND TRICYCLIC AMINOALDEHYDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-22 | — | — | US | disclosed |
| EP-0405543-A2 | Photosensitive leuco dye containing electrostatic master with printout image | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0397529-A2 | Photohardenable electrostatic element with improved environmental latitude | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-11-14 | — | — | EP | disclosed |
| EP-0390103-A2 | High resolution superimposed images from photopolymer electrographic master | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-03 | — | — | EP | disclosed |
| US-4960660-A | RADIATION EXPOSURE, STRIPPING COVER SHEET, LAMINATION, PEELING TEMPORARY SURFACE, CHARGING, DEVELOPING | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-02 | — | — | US | disclosed |
| US-4945020-A | MIXTURE OF POLYMIERC BINDER, PHOTOOXIDANT, LEUCO DYE, HALOGENATED HYDROCARBON AND PLASTICIZER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-07-31 | — | — | US | disclosed |
| EP-0374875-A2 | Visible sensitizers for photopolymerizable compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4917977-A | METHINE DYE, ETHYLENICALLY UNSATURATED COMPOUND AND FREE RADICAL GENERATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-17 | — | — | US | disclosed |
| EP-0352774-A1 | Photopolymerisation sensitizer active at longer wavelength | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-01-31 | — | — | EP | disclosed |
| US-4897327-A | Correct-reading images from photopolymer electrographic master | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0343666-A2 | Correct-reading images from photopolymer electrographic master | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
| US-4876257-A | 6-Substituted purinyl piperazine derivatives useful as cardiotonic and antiarrhythmic agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0331511-A1 | 6-Substituted purinyl piperazine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4859551-A | Process for preparing positive and negative images using photohardenable electrostatic master | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-08-22 | — | — | US | disclosed |
| US-4849314-A | PHOTOPOLYMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0315120-A2 | Photohardenable electrostatic master having improved backtransfer and charge decay | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-10 | — | — | EP | disclosed |
| EP-0315121-A2 | Process for preparing positive and negative images using photohardenable electrostatic master | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-10 | — | — | EP | disclosed |
| EP-0315116-A2 | Photohardenable electrostatic master containing electron acceptor or donor | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4818660-A | POLYMERIC BINDER AND UNSATURATED COMPOUND, PHOTOINITIATOR, BAS IC DYE, LEUCO DYE AND STRONG ACID | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0301422-A2 | Thiomethyl and sulfinylmethyl derivatives having gastric acid antisecretory activity, processes for the preparation thereof and pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.p.A. (IT) | 1989-02-01 | — | — | EP | disclosed |
| US-4732831-A | MONOMERS, TONERS, CHAIN TRANSFER AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| US-4720497-A | 6-purinyl N-/2-chloroethyl/carbamate and thiocarbamate and process for the preparation thereof | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1988-01-19 | — | — | US | disclosed |
| EP-0243934-A2 | Xeroprinting with photopolymer master | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-11-04 | — | — | EP | disclosed |
| EP-0071282-B1 | URACIL DERIVATIVES AND USE THEREOF IN PHOTOGRAPHIC PRODUCTS AND PROCESSES | POLAROID CORPORATION (US) | 1986-09-24 | — | — | EP | disclosed |
| EP-0186454-A2 | 6-Purinyl N-(2-chloroethyl) carbamate and thiocarbamate, a process for their preparation and use thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1986-07-02 | — | — | EP | disclosed |
| US-4442290-A | DERIVATIVES OF PYRIMIDINEDIONE | POLAROID CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
| EP-0071282-A2 | Uracil derivatives and use thereof in photographic products and processes | POLAROID CORPORATION (US) | 1983-02-09 | — | — | EP | disclosed |
| US-4350754-A | FOR PHOTOGRAPHIC FILMS; URACIL DERIVATIVES | POLAROID CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| US-4350754-A | FOR PHOTOGRAPHIC FILMS; URACIL DERIVATIVES | POLAROID CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (47 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259889-A1 | Protein Binding Compounds | FABP1, FABP3, FABP2 | PI4KA 4618/4885PI4K2B 4565/4885PI4K2A 4742/4885 |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PI4KA 80/4885PI4K2B 173/4885PI4K2A 191/4885 |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20240024329-A1 | COMBINATION DRUG PRODUCTS FOR TREATING PATIENTS SUFFERING FROM ONE OR MORE MEDICAL CONDITIONS CAUSED BY CORONAVIRUS INFECTION, INCLUDING BY SARS-CoV-2, ITS ALPHA, BETA, DELTA, OR OMICRON VARIANTS AND SUB VARIANTS | TPMT, DDX6, MTAP | PI4KA 4644/4885PI4K2B 4497/4885PI4K2A 4578/4885 |
| US-20080103110-A1 | Compounds | ATIC, CDA, PAICS | PI4KA 3502/4885PI4K2B 4175/4885PI4K2A 4105/4885 |
| US-20170340633-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20050096293-A1 | Analogs of nitrobenzylthioinosine | NUDT1, TYMP, NNMT | PI4KA 2857/4885PI4K2B 2555/4885PI4K2A 2812/4885 |
| US-10645936-B2 | Bacillus megaterium bioactive compositions and metabolites | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PI4KA 80/4885PI4K2B 173/4885PI4K2A 191/4885 |
| US-20180360832-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20200267991-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20140154772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PI4KA 80/4885PI4K2B 173/4885PI4K2A 191/4885 |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20140051571-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | PI4KA 16/4885PI4K2B 31/4885PI4K2A 51/4885 |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | PI4KA 6/4885PI4K2B 22/4885PI4K2A 20/4885 |
| US-11986479-B2 | Combination drug products for treating patients suffering from one or more medical conditions caused by coronavirus infection, including by SARS-CoV-2, its alpha, beta, delta, or omicron variants and sub variants | TPMT, DDX6, MTAP | PI4KA 4644/4885PI4K2B 4497/4885PI4K2A 4578/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PI4KA 80/4885PI4K2B 173/4885PI4K2A 191/4885 |
| US-20110021541-A1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | PIK3CD, PI4KB, PI4KA | PI4KA 3/4885PI4K2B 7/4885PI4K2A 12/4885 |
| US-20170049772-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 4/4885PI4K2B 11/4885PI4K2A 12/4885 |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3R5, PIK3CA | PI4KA 6/4885PI4K2B 18/4885PI4K2A 23/4885 |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | PIK3CD, PIK3CA, PIK3CG | PI4KA 10/4885PI4K2B 18/4885PI4K2A 27/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PI4KA 80/4885PI4K2B 173/4885PI4K2A 191/4885 |
| US-20200093828-A1 | CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CDC7, TARDBP, CDC14A | PI4KA 620/4885PI4K2B 704/4885PI4K2A 650/4885 |
| US-11446304-B2 | CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions | CDC7, TARDBP, CDC14A | PI4KA 620/4885PI4K2B 704/4885PI4K2A 650/4885 |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20200061062-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-11959065-B2 | Bacillus megaterium bioactive compositions and metabolites | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20210346388-A1 | CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions | CDC7, TARDBP, TDP1 | PI4KA 1151/4885PI4K2B 918/4885PI4K2A 924/4885 |
| US-20070099871-A1 | Bioreductively-activated prodrugs | CBR3, OPRD1, CBR1 | PI4KA 3567/4885PI4K2B 3535/4885PI4K2A 4107/4885 |
| US-20150305346-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PI4KA 80/4885PI4K2B 173/4885PI4K2A 191/4885 |
| US-20070142370-A1 | Azabicyclooctan-3-one derivatives and use thereof | CCNA1, CCNY, MALT1 | PI4KA 1818/4885PI4K2B 1430/4885PI4K2A 1858/4885 |
| US-20220315885-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 16/4885 |
| US-20240115705-A1 | Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) | BTN3A1, BTF3, CD274 | PI4KA 3505/4885PI4K2B 3576/4885PI4K2A 3334/4885 |
| US-20210060016-A1 | ANTICANCER AGENT | MAP2, TNKS, TNKS1BP1 | PI4KA 1064/4885PI4K2B 1104/4885PI4K2A 968/4885 |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-10010550-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-11384332-B2 | Bacillus megaterium bioactive compositions and metabolites | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20170198335-A1 | Stabilization of Non-Denatured Polypeptides, Nucleic Acids, and Exosomes in a Blood Sample at Ambient Temperatures | EXOSC5, EXOSC9, EXOSC10 | PI4KA 3429/4885PI4K2B 3497/4885PI4K2A 2974/4885 |
| US-10398695-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PI4KA 5/4885PI4K2B 11/4885PI4K2A 15/4885 |
| US-20180042241-A1 | BACILLUS MEGATERIUM BIOACTIVE COMPOSITIONS AND METABOLITES | GZMB, VIP, BAX | PI4KA 1375/4885PI4K2B 587/4885PI4K2A 1321/4885 |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, IP6K2, IP6K3 | PI4KA 17/4885PI4K2B 18/4885PI4K2A 20/4885 |
| US-20030147844-A1 | Polymeric thiol-linked prodrugs | MPST, TST, SHMT1 | PI4KA 3477/4885PI4K2B 3504/4885PI4K2A 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.